Pharmacologic class (EPC) · 2 drug pages
Complement 5a receptor antagonist: adverse event reports filed with FDA
6,196 reports list a drug in this class as a suspect or interacting product, 2021–2026.
- 6,196
- reports across the class
- 0% of all reports
- 2,091
- reports, 12 months to June 2026
- 1,390 in the 12 months before
- 72.8%
- marked serious by the reporter
- 57.4% across all reports
- 2
- drugs with a page
- brand and generic names counted separately
Complement 5a receptor antagonist is a pharmacologic class (an FDA Established Pharmacologic Class) with 2 drug pages on this site. Together those drugs are listed as a suspect or interacting product in 6,196 adverse event reports received by FDA, 0% of the database, from September 2021 to June 2026.
2,091 reports arrived in the 12 months to June 2026, up 50% from 1,390 in the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. 72.8% of the class's reports are marked serious, 10.1% record death among the outcomes and 45.8% record hospitalisation, as reported.
Across the class the reactions recorded most often are hospitalisation (15%), death (6.1%) and off label use (4.9%). The class median share shown beside each term is the middle value across the member drugs; it is the comparison used on every drug page in this class.
The members table is ordered by report count for navigation only. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."
Drugs in the class
| Drug | Name type | Reports | Latest 12 months | Marked serious | Top term recorded |
|---|---|---|---|---|---|
| TavneosAvacopan | brand | 5,627 | 1,884 | 70.7% | Hospitalisation |
| Avacopan | generic | 569 | 207 | 93.7% | Off label use |
Ordered by report count for navigation only. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."
Reports by month, five years
FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.
Reactions recorded across the class
share of class reports recording the termmedian drug in the class
- Hospitalisationadmission to hospital15%928
- Deaththe patient died; cause not stated by this term6.1%379
- Off label useused for a purpose or in a way not on the label4.9%302
- Therapy interrupted4.6%288
- Diarrhoealoose or frequent stools4.1%251
- Fatiguetiredness3.9%242
- Nauseafeeling sick3.8%236
- Pneumonialung infection3.5%216
- Headachehead pain2.7%170
- Covid-19COVID-19 infection2.6%164
- Product dose omission issuea dose was missed2.5%154
- Dialysisdialysis2.2%135
- Infectionan infection, type not specified2.2%135
- Dyspnoeashortness of breath2%122
- Liver disorder2%122
- Rashskin rash2%122
- Drug ineffectivethe medicine did not work as expected1.9%119
- Hepatic function abnormal1.8%114
- Illness1.7%107
- Dizzinesslight-headedness or unsteadiness1.7%104
- Drug-induced liver injury1.7%104
- Unevaluable eventthe event could not be assessed1.7%104
- Vomitingbeing sick1.6%99
- Hypertensionhigh blood pressure1.6%97
- Abdominal discomfortstomach discomfort1.5%95
Solid bar: share of all class reports. Hollow bar: the median share across the 2 member drugs, the reference used on each member's page. One report can record several terms.
Outcomes, patients and reporters
Outcomes recorded
Patient age
Who reported
Grey bar: all 20,646,523 reports in the database. Outcome flags are as the reporter set them and are not verified by FDA.
Questions about Complement 5a receptor antagonist reports
Which drugs are in the Complement 5a receptor antagonist class on this site?
Tavneos and Avacopan. Class membership comes from the pharmacologic class (EPC) on the drug's FDA label.
How many reports does the class have?
6,196 reports through June 2026, 2,091 of them in the latest 12 months. A report listing two drugs of the class counts once for each.
What reactions are recorded most often?
hospitalisation (15%), death (6.1%), off label use (4.9%), therapy interrupted (4.6%) and diarrhoea (4.1%).
Can the members table be used to rank the drugs?
No. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic." Drugs differ in how many people take them, in the conditions they treat, in time on the market and in how diligently reports are collected.
How do I report an adverse event?
Through FDA MedWatch (Form FDA 3500, or 1-800-FDA-1088) or to the manufacturer. See the guide on how to report.
Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. A class is the Established Pharmacologic Class most often attached to a drug's reports by openFDA's label harmonisation, or from the NDC Directory where reports carry none. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.
Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.